Treace John T.'s Form 4 filing
Treace Medical Concepts, Inc. (TMCI) · filed Jun 11, 2026
- Accession no.
- 0001193125-26-267800
- Filed
- Jun 11, 2026
- Trade date
- Jun 10-11, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $210.8K. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001193125-26-268606 (Jun 12, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Treace John T.CIK 0001856380 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9300 to $4.1000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9600 to $4.1700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.